- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02215395
An Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication Miconazole Nitrate on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring in Normal Ovulating Women
August 11, 2017 updated by: Population Council
Phase 1, Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication (Miconazole Nitrate) on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring Releasing a Daily Dose of 150 ug of NES and 15 ug of EE
To evaluate the pharmacokinetics (PK) of EE and NES released from the CVR in the presence of a single dose and multiple doses of antimycotic co-medication (miconazole nitrate suppository or cream).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Missouri
-
Springfield, Missouri, United States, 65802
- QPS Bio-Kinetic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 33 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy women, inclusive of ages 18-35* years at the enrollment visit
- Intact uterus and both ovaries
- Prior history of regular menstrual cycles that usually occur every 28 ± 7 days when not using hormonal contraception; if postpartum or post-abortal, history of regular menstrual cycles of 21-35 days in length and resumption of at least one cycle with a cycle length consistent with her past cycles
- In the opinion of the investigator, able to comply with the protocol, e.g. live within the study site catchment area or within a reasonable distance from the study site
- May be sterilized or at risk of becoming pregnant
- Willing to use a non-hormonal method of contraception for one month prior to the initial insertion of the NES/EE CVR and the one month washout period
- Willing to abstain from sexual intercourse during the miconazole nitrate treatment period(s)
- Signed informed consent prior to entry into the trial
Exclusion Criteria:
- Known hypersensitivity to estrogens or progestins
- Pregnant, trying to become pregnant, or breastfeeding
- Known hypersensitivity to silicone rubber
- Undiagnosed abnormal vaginal bleeding
- Undiagnosed vaginal discharge, vaginal lesions or abnormalities. Subjects diagnosed at screening with a Chlamydia or gonococcus infection may be included in the trial following treatment; partner treatment is also recommended. Investigators should make a determination if subjects are at high risk for reinfection, e.g., multiple sex partners, untreated partner, and whether such subjects can be included
- History of pelvic inflammatory disease since the subject's last pregnancy
- History of toxic shock syndrome
- In accordance with the Bethesda system of classification: Women with a current (within the last 20 months) abnormal Pap smear suggestive of high-grade pre-cancerous lesion (s), including HGSIL
- Cystoceles or rectoceles or other anatomical abnormality that would preclude use of a vaginal ring
- Women planning to undergo major surgery during the trial
- Women who smoke 15 cigarettes or more per day must be evaluated by the PI for inclusion based on risk factors that would increase their risk for cardiovascular disease and thromboembolism, e.g., lipid levels, glucose level, BP, BMI, family history of cardiovascular disease at a young age
- Current or past thrombophlebitis or thromboembolic disorders
- History of venous thrombosis or embolism in a first-degree relative, <55 years of age suggesting a familial defect in the blood coagulation system, which in the opinion of the PI, suggests that use of a hormonal contraceptive could pose a significant risk
- Cerebrovascular or cardiovascular disease
- History of retinal vascular lesions, unexplained partial or complete loss of vision
- Known or suspected carcinoma of the breast
- Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
- Past history of any other carcinoma unless in remission for more than five years
- Current or history of medically diagnosed severe depression, which, in the opinion of the investigator, could be exacerbated by the use of a hormonal contraceptive
- Headaches with focal neurological symptoms
- Severe constipation in the opinion of the investigator
- History of cholestatic jaundice of pregnancy or jaundice with prior steroid use
- Benign or malignant liver tumors; active liver disease
- Diastolic blood pressure (BP) >85 mm Hg and/or systolic BP >135 mm Hg after 5-10 minutes rest (at screening)
- Known or suspected alcoholism or drug abuse within their lifetime
- Elevated serum fasting clinical chemistry values or complete blood count (CBC) values designated clinically significant by the investigator and/or medically qualified sub-investigator
- Screening hemoglobin levels less than 12.5 g/dL or hematocrit less than 38%.
- Participation in another clinical trial involving an investigational drug within the last 30 days (prior to screening)
- BMI >29
- Use of liver enzyme inducers on a regular basis
- Use of monthly injectable contraceptives, unless suspended 2 months before initiation of the treatment. Use of Depo-Provera [depo-medroxyprogesterone (DMPA)] unless suspended 6 months before treatment
- Current use of implanted hormonal contraceptives, including Mirena [progestin containing intrauterine system (IUS)], Jadelle, Norplant, Implanon or Nexplanon (if now available in the USA).**
- Known HIV, Hepatitis B or Hepatitis C infection
- History of frequent vaginal infections in the opinion of the investigator
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CVR treatment cycle
Women who meet all inclusion and no exclusion criteria will be randomized to the first treatment cycle with the CVR alone followed by the second treatment cycle with the CVR and miconazole (one of three dosing regimens) or the first treatment cycle with the CVR and miconazole followed by the second treatment cycle with the CVR alone.
|
Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Drug Drug Interaction of NES/EE CVR and topical anti-fungal medication
Time Frame: Week 12
|
To evaluate adverse reactions to a topical anti-fungal medication when used in conjunction with the NES/EE CVR
|
Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Dennis Morrison, MD, QPS-Biokinetic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
May 29, 2014
First Submitted That Met QC Criteria
August 11, 2014
First Posted (Estimate)
August 13, 2014
Study Record Updates
Last Update Posted (Actual)
August 15, 2017
Last Update Submitted That Met QC Criteria
August 11, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Drug-Related Side Effects and Adverse Reactions
- Physiological Effects of Drugs
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Estrogens
- Contraceptive Agents, Hormonal
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Hormonal
- Estradiol
- Contraceptive Agents
- Ethinyl Estradiol
Other Study ID Numbers
- 571
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antifungal Drug Adverse Reaction
-
Assiut UniversityNot yet recruitingAntiarrhythmic Drug Adverse Reaction
-
Romanian Society of Anesthesia and Intensive CareUnknownGeneral Anesthetic Drug Adverse ReactionRomania
-
University Hospital Hradec KraloveCompletedGeneral Anesthetic Drug Adverse ReactionCzech Republic
-
Damanhour Teaching HospitalRecruitingGeneral Anesthetic Drug Adverse ReactionEgypt
-
Poznan University of Medical SciencesCompletedGeneral Anesthetic Drug Adverse ReactionPoland
-
Sun Yat-sen UniversityUnknownNon-steroidal Anti-inflammatory Drug Adverse ReactionChina
-
Brigham and Women's HospitalNational Institutes of Health (NIH); Atrius HealthCompletedAging | Adverse Drug Event | Benzodiazepine Sedative Adverse Reaction | Anticholinergic Adverse ReactionUnited States
-
Assiut UniversityUnknownAntiviral Drug Adverse Reaction
-
Izmir Ataturk Training and Research HospitalNot yet recruitingPsychotropic Agents Causing Adverse Effects in Therapeutic Use | Anticholinergic Adverse Reaction | Anticholinergic Syndrome | Antiarrhythmic Drug Adverse Reaction | Antiparkinsonism Drugs Causing Adverse Effects in Therapeutic Use | Antispasmodic Adverse Reaction
-
Brigham and Women's HospitalMassachusetts General Hospital; National Institutes of Health (NIH); National...Active, not recruitingAging | Adverse Drug Event | Benzodiazepine Sedative Adverse Reaction | Anticholinergic Adverse ReactionUnited States
Clinical Trials on NES/EE CVR
-
Health DecisionsEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsUnknownFemale Contraception | Healthy WomenUnited States
-
Population CouncilEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedContraceptionDominican Republic, United States, Chile, Australia, Brazil, Finland, Hungary, Sweden
-
Mondelēz International, Inc.Provident Clinical ResearchCompletedType 2 Diabetes MellitusUnited States
-
Health DecisionsEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedContraceptionUnited States
-
Centre Hospitalier Universitaire DijonTerminatedCoronary Artery DiseaseFrance
-
DiaSorin Molecular LLCNot yet recruitingCoronavirus Disease 2019 | Influenza A | Influenza Type BAustralia
-
St George's, University of LondonNeovii BiotechWithdrawnMitochondrial Diseases | Inborn Errors of Metabolism | Metabolic Disease
-
Health DecisionsEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Wake Forest University Health SciencesMayo Clinic; National Institute of Diabetes and Digestive and Kidney Diseases... and other collaboratorsRecruitingPhysical ActivityUnited States